These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36367967)

  • 1. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer.
    Faraoni EY; O'Brien BJ; Strickland LN; Osborn BK; Mota V; Chaney J; Atkins CL; Cen P; Rowe J; Cardenas J; Poulsen KL; Wray CJ; Thosani NC; Bailey-Lundberg JM
    Cancer Immunol Res; 2023 Jan; 11(1):4-12. PubMed ID: 36367967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.
    Moond V; Maniyar B; Harne PS; Bailey-Lundberg JM; Thosani NC
    Explor Target Antitumor Ther; 2024; 5(5):1056-1073. PubMed ID: 39351436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated with Endoscopic Ultrasound Guided Radiofrequency Ablation.
    Lawrence PV; Desai K; Wadsworth C; Mangal N; Kocher HM; Habib N; Sadanandam A; Sodergren MH
    Curr Oncol; 2022 Sep; 29(10):6754-6763. PubMed ID: 36290808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer.
    Scopelliti F; Pea A; Conigliaro R; Butturini G; Frigerio I; Regi P; Giardino A; Bertani H; Paini M; Pederzoli P; Girelli R
    Surg Endosc; 2018 Sep; 32(9):4022-4028. PubMed ID: 29766302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer.
    Fei Q; Pan Y; Lin W; Zhou Y; Yu X; Hou Z; Yu X; Lin X; Lin R; Lu F; Guan H; Huang H
    Cell Death Dis; 2020 Jul; 11(7):589. PubMed ID: 32719347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing EUS-guided radiofrequency ablation in unresectable pancreatic ductal adenocarcinoma: a single-center historic cohort study.
    Robles-Medranda C; Del Valle R; Puga-Tejada M; Arevalo-Mora M; Cunto D; Egas-Izquierdo M; Estrada-Guevara L; Bunces-Orellana O; Moreno-Zambrano D; Alcivar-Vasquez J; Alvarado-Escobar H; Merfea RC; Barreto-Perez J; Rodriguez J; Calle-Loffredo D; Pitanga-Lukashok H; Baquerizo-Burgos J; Tabacelia D
    Gastrointest Endosc; 2024 Aug; 100(2):250-258. PubMed ID: 38518978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma.
    Thosani N; Cen P; Rowe J; Guha S; Bailey-Lundberg JM; Bhakta D; Patil P; Wray CJ
    Sci Rep; 2022 Oct; 12(1):16516. PubMed ID: 36192558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?
    Geboers B; Ruarus AH; Nieuwenhuizen S; Puijk RS; Scheffer HJ; de Gruijl TD; Meijerink MR
    Chin Clin Oncol; 2019 Dec; 8(6):61. PubMed ID: 31865711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
    Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
    World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
    Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
    Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Ma H; Mo S; Yu S; Lu Z; Chen J
    Front Immunol; 2022; 13():1027459. PubMed ID: 36325339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
    Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
    Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.